News und Analysen
Dexcom Reports Second Quarter 2022 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2022.
Second Quarter 2022 Financial Highlights:
-
Revenue grew 17% versus the same
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2022 financial results after the market
DGAP-News: Burcon JV, Merit Functional Foods Achieves Significant Innovation in a 100% Protein-based Solution to Replace Methylcellulose in Meat Alternatives
Valbiotis meldet den Abschluss der Rekrutierung für die klinische Phase II/III-Studie REVERSE-IT mit TOTUM•63 gegen Prädiabetes in Partnerschaft mit Nestlé Health Science
Valbiotis (FR0013254851 - ALVAL, PEA/KMU-qualifiziert) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Novocure Reports Second Quarter 2022 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
PFIZER REPORTS SECOND-QUARTER 2022 RESULTS
Pfizer Inc. (NYSE: PFE) reported strong financial results for second-quarter 2022 and updated certain components of 2022 financial guidance(4). Pfizer reaffirmed its previous 2022 revenue guidance
Valbiotis Announces Completion of Recruitment for the Phase II/III REVERSE-IT Clinical Study With TOTUM•63 Against Prediabetes, in Partnership With Nestlé Health Science
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
ICON plc (NASDAQ: ICLR) ) (“ICON”), a world-leading healthcare intelligence and clinical research organisation, today announced that all resolutions at the Annual General Meeting of the Company
Chemed Reports Second-Quarter 2022 Results
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will
Acadia Healthcare Reports Second Quarter 2022 Results and Raises 2022 Guidance
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2022.
Second Quarter Highlights
-
Revenue totaled $651.7 million, an
ICON Reports Second Quarter 2022 Results
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the second quarter ended June 30, 2022.
CEO Dr. Steve
DGAP-Adhoc: MagForce AG: Provisional insolvency administrator appointed by the court
Agilent 2022 Early Career Professor Award Presented to Stefanos Nikolaidis
Agilent Technologies Inc. (NYSE: A) announced today that Stefanos Nikolaidis Ph.D. has received the Agilent 2022 Early Career Professor Award. Dr. Stefanos Nikolaidis is an Assistant Professor of
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Novocure today announced the recipients of the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The AACR-Novocure Grants for Tumor Treating Fields Research Program
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
DGAP-Adhoc: Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
QIAGEN ergänzt digitales PCR-Portfolio QIAcuity um neue Biopharma-Produkte und führt Expert Custom Assay Design Service ein
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute mehrere Erweiterungen seiner Instrumente für digitalen PCR (dPCR) der QIAcuity-Serie bekannt. Mit den Neuerungen soll der Einsatz des
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a series of enhancements for its QIAcuity series of digital PCR (dPCR) instruments designed to drive greater use among customers
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a series of enhancements for its QIAcuity series of digital PCR (dPCR) instruments designed to drive greater use among customers